Cas9 Protein Outperforms mRNA in Lipid Nanoparticle-Mediated CFTR Repair

Area of Science:

• Biotechnology
• Gene Therapy
• Nanomedicine

Background:

• Lipid nanoparticles (LNPs) are advanced delivery systems for nucleic acid cargo.
• CRISPR/Cas9 gene editing holds promise for treating genetic diseases like cystic fibrosis (CF).

Purpose of the Study:

• To compare the efficacy of LNP-delivered Cas9 protein versus mRNA for in vivo gene editing.
• To evaluate the potential for correcting CFTR gene mutations using CRISPR/Cas9 LNP technology.

Main Methods:

• Delivery of Cas9 protein and mRNA via LNPs into lung tissue.
• Assessment of in vivo gene editing efficiency and CFTR protein functional recovery.
• Comparative analysis of CRISPR/Cas9 editing outcomes.

Main Results:

• Cas9 protein LNPs demonstrated superior in vivo lung editing compared to Cas9 mRNA LNPs.
• CRISPR/Cas9 delivered by protein LNPs resulted in more effective gene correction and CFTR protein function restoration.
• Optimized LNP delivery of Cas9 protein enhances therapeutic potential for CF.

Conclusions:

• Cas9 protein LNPs are a more effective delivery strategy than mRNA LNPs for CRISPR/Cas9-mediated gene editing in cystic fibrosis.
• This study highlights the potential for optimizing LNP formulations for targeted gene therapies.
• CRISPR/Cas9 LNP technology shows promise for developing corrective therapeutics for genetic diseases.